Zydus Life Sciences Acquires LiqMeds Group
New subsidiary specializes in development of oral liquid products.
Zydus Lifesciences Limited announced that through Zydus Pharmaceuticals UK Limited, a wholly owned subsidiary, it has officially acquired LiqMeds Group, a company focused on the development, manufacturing, and supply of oral liquid products for the global market. Under terms of the acquisition, Zydus will pay an upfront amount of approximately $82.6 million with the potential for further yearly payments until 2026 depending on achievement of certain agreed milestones.
“We believe that liquid orals is a large, growing market and serves unmet needs with significant new market expansion opportunities,” said Sharvil Patel, managing director, Zydus Life Sciences, in a company press release. “In line with our patient-centric approach, we believe that oral liquid formulations would help geriatric and paediatric patients, bringing in greater ease of convenience and therapy compliance.”
Reference: Zydus acquires UK based LiqMeds® Group. Zydus Life Sciences. October 31, 2023. Accessed October 31, 2023. https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-acquires-UK-based-LiqMeds--Group---31-10-2023.pdf
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
